Does the COMT Val158Met Met allele reduce COMT activity and slow catecholamine breakdown?

The COMT Val158Met (rs4680) polymorphism is a well-characterized functional genetic variant that profoundly influences catecholamine neurotransmitter regulation in the central nervous system.

Molecular mechanisms

• Enzyme stability: The rs4680 single-nucleotide polymorphism causes a substitution of valine (Val) to methionine (Met) at codon 158 of the catechol-O-methyltransferase enzyme.
• Reduced activity: This structural modification creates a thermolabile enzyme that is unstable at physiological temperature (37°C) and undergoes accelerated cellular degradation.
• Trimodal distribution: Consequently, individuals homozygous for the Met allele (Met/Met) exhibit a substantial 60% to 75% reduction in COMT enzymatic activity (retaining only 25% to 40% of the active enzyme levels observed in Val/Val homozygotes).

Impact on catecholamine clearance

• Impaired O-methylation: Under normal conditions, COMT inactivates catecholamines—specifically dopamine, epinephrine, and norepinephrine—via O-methylation. The genetic reduction in COMT activity directly delays this metabolic breakdown.
• Prefrontal cortex vulnerability: This delayed clearance has a pronounced effect in the prefrontal cortex. Because this brain region has exceptionally low levels of dopamine active transporters (DAT) to clear synaptic transmitters, it relies heavily on COMT enzymatic breakdown to terminate catecholaminergic signaling.

Bottom line

• The COMT Val158Met Met allele creates a highly thermolabile enzyme, reducing overall COMT activity by 60% to 75% (a 3- to 4-fold decrease) and significantly delaying the clearance of dopamine, epinephrine, and norepinephrine, particularly within the prefrontal cortex.